RAM
IKT icon

Redmond Asset Management’s Inhibikase Therapeutics IKT Stock Holding History

Redmond Asset Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,560
Closed -$42.3K – 161
2024
Q1 		$42.3K Sell
19,560
-84
-0.4% -$185 0.01% 150
2023
Q4 		$24.9K Sell
19,644
-1,333
-6% -$1.38K 0.01% 157
2023
Q3 		$29.2K Buy
20,977
+1
+0% +$2 0.01% 159
2023
Q2 		$75.7K Buy
20,976
+8
+0% +$30 0.02% 157
2023
Q1 		$82.7K Hold
20,968
– – 0.03% 161
2022
Q4 		$62.9K Buy
20,968
+555
+3% +$2.2K 0.02% 166
2022
Q3 		$111K Sell
20,413
-34
-0.2% -$179 0.04% 165
2022
Q2 		$91K Hold
20,447
– – 0.03% 181
2022
Q1 		$182K Buy
+20,447
New +$165K 0.05% 182

Other funds holding IKT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return

Redmond Asset Management's IKT Position: Q2 2024 in Review

Redmond Asset Management sold out of Inhibikase Therapeutics (IKT) in Q2 2024, closing a stake of 19,560 shares — an estimated $42.3K sold.

Redmond Asset Management first reported a position in IKT in Q1 2022 and held it in 9 quarters. The position peaked at $182K in Q1 2022. 12 funds tracked by Wall St. Rank hold IKT as of Q2 2024.

  • Redmond Asset Management reported no remaining Inhibikase Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Redmond Asset Management sold 19,560 Inhibikase Therapeutics shares in Q2 2024, an estimated $42.3K.
  • Redmond Asset Management first reported a position in Inhibikase Therapeutics in Q1 2022 and held it in 9 quarters.
  • Redmond Asset Management's Inhibikase Therapeutics position peaked at $182K in Q1 2022.
  • 12 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2024.

Based on Redmond Asset Management's 13F filing for Q2 2024, filed 9 Aug 2024.